LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

DexCom Inc

Fermé

SecteurSoins de santé

69.73 1.19

Résumé

Variation du prix de l'action

24h

Actuel

Min

68.85

Max

71.01

Chiffres clés

By Trading Economics

Revenu

-68M

200M

Ventes

-68M

1.2B

P/E

Moyenne du Secteur

29.644

50.958

BPA

0.56

Marge bénéficiaire

16.738

Employés

11,000

EBITDA

-52M

337M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+19.86% upside

Dividendes

By Acuity

Prochains Résultats

29 juil. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3B

27B

Ouverture précédente

68.54

Clôture précédente

69.73

Sentiment de l'Actualité

By Acuity

18%

82%

35 / 342 Classement par Healthcare

DexCom Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

À Propos DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat